Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a US-based clinical stage biotechnology company, announced on Monday that it has named Patricia A Bradford as its new independent director.
Bradford has over four decades of executive HR experience and a financial acumen having received CPA accreditation during her time at Deloitte. She has held various roles of increasing responsibility at Unisys Corporation. She has worked at Deloitte, in positions in the Audit and Tax departments. Presently, Bradford offers HR consulting services to a wide range of companies, concentrating on offering individual coaching for senior executives and high potential employees recommended by management.
Robert Bitterman, Phio Pharmaceuticals chairman, said, 'We are delighted to welcome Patricia to the Phio board. I am certain that her wealth of experience as an executive at rapidly growing international conglomerates and in HR management will bring tremendous value to the Board. We believe that Patricia will be an effective steward of the company and counsellor to the management team.'
ELIAS Animal Health names new chief revenue officer
enGene Holdings names new senior vice president, Urologic Oncology and Clinical Development
HealthTrackRx names new chief medical officer
PureTech announces launch of Seaport Therapeutics with USD100m Series A financing
Orsini Specialty Pharmacy names new CFO and EVP of Trade Relations and Account Management
Enable Biosciences names new chief financial officer
Cadenza Bio names new director
Ligand Pharmaceuticals launches Pelthos Therapeutics to drive ZELSUVMI commercialisation